A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis-Reference-Cited by-同舟云学术

A randomized trial comparing 4.8 vs. 2.4g/day of oral mesalazine for maintenance of remission in ulcerative colitis

Published:2015-11 Issue:11 Volume:47 Page:933-937
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

Pica Roberta,Cassieri Claudio,Cocco Andrea,Zippi Maddalena,Marcheggiano Adriana,De Nitto Daniela,Avallone Eleonora Veronica,Crispino Pietro,Occhigrossi Giuseppe,Paoluzi Paolo

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Factors predicting of response to cyclosporine treatment for severe, steroid resistant ulcerative colitis;Rowe;American Journal of Gastroenterology,2000

2. Systematic review: how effective are the usual treatments for ulcerative colitis?;Bebb;Alimentary Pharmacology and Therapeutics,2004

3. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial Pentasa Study Group;Hanauer;American Journal of Gastroenterology,1993

4. Sulfasalazine revisited. A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis;Sutherland;Annals of Internal Medicine,1993

5. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid;Dew;British Medical Journal (Clinical Research Ed.),1982

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management and treatment optimization of patients with mild to moderate ulcerative colitis;Expert Review of Clinical Immunology;2023-12-07

2. Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus;Journal of Clinical Medicine;2023-11-04

3. Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction;Inflammatory Intestinal Diseases;2023

4. De-escalation of Therapy in Patients with Quiescent Inflammatory Bowel Disease;Gut and Liver;2022-11-14

5. Fecal microbiota transplantation for patients with active ulcerative colitis: A cost‐effectiveness analysis;Journal of Gastroenterology and Hepatology;2022-10-09